Literature DB >> 1970934

Expression of mdr1 and gst-pi in human breast tumours: comparison to in vitro chemosensitivity.

W N Keith1, S Stallard, R Brown.   

Abstract

Increased expression of the mdr1 gene, encoding the 175 kDa P-glycoprotein, and the gst-pi gene, encoding the anionic isozyme of glutathione S-transferase (GST), have previously been detected in continuous human breast cancer cell lines selected in vitro for resistance to doxorubicin. In this present study we have measured RNA levels of mdr1 and gst-pi in primary human breast tumour biopsies prior to chemotherapy and from tumours which have different inherent responses to doxorubicin treatment, including colon, head and neck squamous cell carcinomas and myeloid leukaemias. Detectable levels of mdr1 mRNA was observed in 25 out of 49 breast tumours, with up to a 100-fold range in expression. A narrower range of gst-pi expression has also been observed in these tumours. Chemosensitivity of cells grown in short-term culture from some of the breast tumours has been measured by an in vitro colony forming assay in the presence of doxorubicin. Comparison of the dose of doxorubicin causing 50% inhibition of growth (ID50) with RNA levels showed that the tumours with high mdr1 expression had high ID50, while the more sensitive explants had low mdr1 expression. These results support a role for mdr1 gene expression in determining the response of human breast cancer cells to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970934      PMCID: PMC1971610          DOI: 10.1038/bjc.1990.160

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

Review 1.  The glutathione S-transferases: a group of multifunctional detoxification proteins.

Authors:  W B Jakoby
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1978

Review 2.  Adriamycin. A new anticancer drug with significant clinical activity.

Authors:  R H Blum; S K Carter
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

3.  Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).

Authors:  G Bonadonna; S Monfardini; M De Lena; F Fossati-Bellani; G Beretta
Journal:  Cancer Res       Date:  1970-10       Impact factor: 12.701

4.  Clonal proliferation of cultured nonmalignant and malignant human breast epithelia.

Authors:  H S Smith; S Lan; R Ceriani; A J Hackett; M R Stampfer
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

5.  Reversal of adriamycin resistance by verapamil in human ovarian cancer.

Authors:  A M Rogan; T C Hamilton; R C Young; R W Klecker; R F Ozols
Journal:  Science       Date:  1984-06-01       Impact factor: 47.728

6.  Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy.

Authors:  S Stallard; J G Morrison; W D George; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Use of an efficient method for culturing human mammary epithelial cells to study adriamycin sensitivity.

Authors:  H S Smith; A J Hackett; S Lan; M R Stampfer
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

8.  Response to doxorubicin of cultured normal and cancerous human mammary epithelial cells.

Authors:  H S Smith; M E Lippman; A J Hiller; M R Stampfer; A J Hackett
Journal:  J Natl Cancer Inst       Date:  1985-02       Impact factor: 13.506

9.  The simultaneous extraction of high-molecular-weight DNA and of RNA from solid tumors.

Authors:  P Krieg; E Amtmann; G Sauer
Journal:  Anal Biochem       Date:  1983-10-15       Impact factor: 3.365

10.  Dose response evaluation of adriamycin in human neoplasia.

Authors:  R M O'Bryan; L H Baker; J E Gottlieb; S E Rivkin; S P Balcerzak; G N Grumet; S E Salmon; T E Moon; B Hoogstraten
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

View more
  22 in total

1.  Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.

Authors:  Jan-Hendrik Beumer; Tessa Buckle; Mariet Ouwehand; Niels E F Franke; Luis Lopez-Lazaro; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

Review 2.  MicroRNAs delivered by extracellular vesicles: an emerging resistance mechanism for breast cancer.

Authors:  Wei-xian Chen; Shan-liang Zhong; Ming-hua Ji; Meng Pan; Qing Hu; Meng-meng Lv; Zhou Luo; Jian-hua Zhao; Jin-hai Tang
Journal:  Tumour Biol       Date:  2013-11-22

3.  Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression.

Authors:  J L Moretti; H Azaloux; D Boisseron; J C Kouyoumdjian; J Vilcoq
Journal:  Eur J Nucl Med       Date:  1996-08

4.  High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance.

Authors:  Michael Boettcher; Frank Kischkel; Jörg D Hoheisel
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

5.  Expression of mdr1 gene in human breast primary tumors and metastases.

Authors:  E Hennequin; C Delvincourt; C Pourny; J C Jardillier
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 6.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 7.  Glutathione-related enzymes, glutathione and multidrug resistance.

Authors:  J A Moscow; K H Dixon
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

8.  Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression.

Authors:  M R Müller; K Lennartz; C Boogen; M R Nowrousian; M F Rajewsky; S Seeber
Journal:  Ann Hematol       Date:  1992-11       Impact factor: 3.673

9.  Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines.

Authors:  J R Zalcberg; X F Hu; M Ching; A Wakeling; D M Wall; I C Marschner; M de Luise
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Expression of glutathione-S-transferases alpha and pi in gastric cancer: a correlation with cisplatin resistance.

Authors:  Y Kodera; K Isobe; M Yamauchi; K Kondo; S Akiyama; K Ito; I Nakashima; H Takagi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.